Literature DB >> 34225800

Increased levels of serum IL-17 and induced sputum neutrophil percentage are associated with severe early-onset asthma in adults.

Dandan Chen1, Yu Zhang1, Can Yao1, Binbin Li2, Sinian Li1, Wenwen Liu2, Rongchang Chen3, Fei Shi4.   

Abstract

BACKGROUND: Differences between adult patients with severe early-onset and late-onset asthma have not been well studied.
OBJECTIVES: To determine the phenotypic distinction regarding age at onset in patients with severe asthma.
METHODS: The present study enrolled thirty-two patients with severe early-onset (onset age < 12 years) asthma and thirty-two patients with severe late-onset (onset age > 12 years) asthma. Severe asthma was defined according to Global Initiative for Asthma criteria. The clinical, spirometric, and laboratory parameters were collected for group comparisons.
RESULTS: Among the 64 patients included (mean age, 46.22 ± 13.90 years; 53.1% male), the mean percent of predicted forced expiratory volume in 1 s (FEV1) was 68.43 ± 20.55%. Patients with severe early-onset asthma had a younger age, longer duration of asthma, higher rate of family history, and better small-airway function (MEF25% and MMEF75/25%) compared with severe late-onset asthma. Furthermore, levels of serum IL-17 and sputum neutrophil percentage were significantly higher for patients with severe early-onset asthma (P = 0.016, 0.033, respectively). Multiple logistic regression analysis revealed that increased serum IL-17 (odds ratio = 1.065, P = 0.016) was independently associated with severe early-onset asthma. The combination of serum IL-17 and sputum neutrophil percentage yielded a sensitivity of 80.0% and a specificity of 86.7% for identifying patients with severe early-onset asthma.
CONCLUSIONS: Patients with severe early-onset asthma exhibit elevated levels of serum IL-17 and sputum neutrophil percentage, suggesting a potential role in the pathogenesis of severe early-onset phenotype.

Entities:  

Keywords:  Early-onset; IL-17; Neutrophil; Severe asthma

Year:  2021        PMID: 34225800     DOI: 10.1186/s13223-021-00568-9

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


  2 in total

1.  Exploration in the Mechanism of Zhisou San for the Treatment of Cough Variant Asthma Based on Network Pharmacology.

Authors:  De-Hai Guo; Jin-Ping Hao; Xing-Jie Li; Qing Miao; Qiong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

2.  Early IL-17A Prevention Rather Than Late IL-17A Neutralization Attenuates Toluene Diisocyanate-Induced Mixed Granulocytic Asthma.

Authors:  Shuyu Chen; Li Yu; Yao Deng; Yuanyuan Liu; Lingwei Wang; Difei Li; Kai Yang; Shengming Liu; Ailin Tao; Rongchang Chen
Journal:  Allergy Asthma Immunol Res       Date:  2022-09       Impact factor: 5.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.